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Background: Hydrochlorothiazide (HCTZ) is the thiazide widely prescribed to treat hypertension. (e.g., HCTZ represented 96% of all thiazide 
prescriptions in the Veterans Administration [Ernst 2010].) Some have recently expressed a preference for chlorthalidone (CTDN). However, no head-
to-head randomized trials of the 2 drugs have tested their effect on cardiovascular events (CVEs, i.e., MI, CHF, stroke and related events).
Methods: We conducted a systematic review of all randomized trials in which one arm was based either on HCTZ or CTDN and then conducted 2 
types of network meta-analyses: 1) a drug-adjusted analysis in which each network referenced the same class of drug; 2) an SBP-adjusted analysis 
in which each network referenced the same difference in achieved systolic blood pressure (SBP) between the diuretic and comparison arm.
Results: 9 trials (total participants=78,350) were identified: 3 based on HCTZ; 6 based on CTDN. CTDN was superior to HCTZ in both types of 
analyses: 
Type of Network
Meta-Analysis
SBP-adjusted Drug-adjusted Drug-adjusted
Outcome CVEs CVEs CHF
Percent risk reduction
(95% CL)
17
(3, 30)
21
(12, 28)
23
(2, 39)
2-sided P value 0.020 < 0.0001 0.032
For HCTZ trials, even when the reduction in SBP was identical between the 2 arms, the risk for CVEs in the HCTZ arms was 19% higher than in its 
comparison arms (P=0.016). Compared to HCTZ, the number of patients needed to treat with CTDN to prevent one CVE over 5 years was 25.
Conclusions: CTDN is superior to HCTZ in preventing cardiovascular outcomes. This superiority can not be attributed entirely to HCTZ’s lesser effect 
on office SBP but may be due to pleiotropic effects of alternative medications or to HCTZ’s short duration of action.
